We are live on ! Find out more
VNRX icon

VolitionRx Ltd

0.5010 USD
+0.1618
47.7%
At close Updated Aug 27, 4:00 PM EDT
Pre-market
After hours
0.4929
-0.0081
1.62%
1 day
47.7%
5 days
13.86%
1 month
-43.07%
3 months
-82.96%
6 months
-88.24%
Year to date
-90.82%
1 year
-96.24%
5 years
-99.25%
10 years
-99.34%
 

About: VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.

Employees: 75

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 7.7%
Neutral 92.3%
Negative 0%
Positive
Benzinga
20 hours ago
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations
VolitionRx Limited (NYSE:VNRX) stock is surging on Thursday after the diagnostics company reported a 112% year-over-year revenue surge in the first half of 2026, reaching $1.4 million as it expanded its clinical and commercial operations.
Penny Stock VolitionRx Expands Addressable Markets With Key Diagnostic Validations
Neutral
PRNewsWire
1 day ago
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
112% H1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders HENDERSON, Nev., Aug. 26, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial progress achieved during the first half of 2026.
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
Neutral
PRNewsWire
1 day ago
Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis
Published in Critical Care Medicine , findings confirm high-predictive accuracy for severe sepsis outcomes, driving commercial momentum across Volition's $2.8 billion addressable market. HENDERSON, Nev.
Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis
Neutral
Seeking Alpha
13 days ago
VolitionRx Limited (VNRX) Q2 2026 Earnings Call Transcript
VolitionRx Limited (VNRX) Q2 2026 Earnings Call Transcript
VolitionRx Limited (VNRX) Q2 2026 Earnings Call Transcript
Neutral
PRNewsWire
14 days ago
VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Friday, August 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update
Neutral
PRNewsWire
15 days ago
Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
Removes Centralized Lab Dependency for $3.8 Billion Global Addressable Market for NETosis Testing HENDERSON, Nev., Aug. 12, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that results utilizing its lateral flow prototype are highly correlated with results utilizing Volition's established automated Nu.Q® NETs test in critically ill sepsis patients1 , thereby expanding beyond centralized laboratory testing.
Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
Neutral
PRNewsWire
16 days ago
VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update
Conference call to take place on Friday, August 14 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update
Neutral
PRNewsWire
22 days ago
Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
Targets $36 Billion TAM in Early Cancer Detection and MRD. Company in active discussions with global diagnostic leaders to accelerate commercialization.
Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
Neutral
PRNewsWire
28 days ago
Volition Advances Nu.Q® NETs Platform Towards Commercialization
Consistent international data positions Nu.Q® H3.1 as a potential "game changer" in sepsis management within a $3.8 billion addressable market HENDERSON, Nev., July 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive update highlighting the significant clinical and scientific evidence amassed for its Nu.Q® NETs product.
Volition Advances Nu.Q® NETs Platform Towards Commercialization
Neutral
PRNewsWire
1 month ago
VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test
HENDERSON, Nev., July 7, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of a new clinical study demonstrating the significant prognostic value of its Nu.Q® Cancer Assay in newly diagnosed lung cancer patients, which could help clinicians identify patients' likely outcomes and personalize treatment selection accordingly.
VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test
Price charts implemented using Lightweight Charts™